Literature DB >> 14566919

Over-ruling a group sequential boundary--a stopping rule versus a guideline.

K K Gordon Lan1, John M Lachin, Oliver Bautista.   

Abstract

We evaluate the properties of group sequential procedures where the trial is continued even though the boundary for statistical significance (stopping) to demonstrate effectiveness has been crossed. In this case, one may buy-back the previously spent alpha probability to be re-spent or re-distributed at future looks. We show that such plans using an O'Brien-Fleming-like spending function have a negligible effect on the final type I error probability and on the ultimate power of the study. With a Pocock-like bound, however, there is a small additional loss in power. We also show that this approach can be simplified by using a fixed-sample size Z critical value for future looks after buying-back previously spent alpha, such as using a critical Z value of 1.96 for alpha=0.025. We show that this procedure preserves the type I error probability while incurring a minimal loss in power. In this sense, one still has a stopping boundary rather than simply a guideline. This concept is discussed relative to monitoring procedures for inferiority or futility, and cases where both an upper and lower boundary are employed. Copyright 2003 John Wiley & Sons, Ltd.

Mesh:

Year:  2003        PMID: 14566919     DOI: 10.1002/sim.1636

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

Authors:  Dona L Fleishaker; Juan A Garcia Meijide; Andriy Petrov; Michael David Kohen; Xin Wang; Sujatha Menon; Thomas C Stock; Charles A Mebus; James M Goodrich; Howard B Mayer; Bernhardt G Zeiher
Journal:  Arthritis Res Ther       Date:  2012-01-17       Impact factor: 5.156

2.  Pressure RElieving Support SUrfaces: a Randomised Evaluation 2 (PRESSURE 2): study protocol for a randomised controlled trial.

Authors:  Sarah Brown; Isabelle L Smith; Julia M Brown; Claire Hulme; Elizabeth McGinnis; Nikki Stubbs; E Andrea Nelson; Delia Muir; Claudia Rutherford; Kay Walker; Valerie Henderson; Lyn Wilson; Rachael Gilberts; Howard Collier; Catherine Fernandez; Suzanne Hartley; Moninder Bhogal; Susanne Coleman; Jane E Nixon
Journal:  Trials       Date:  2016-12-20       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.